$11.43
Insights on Dynavax Technologies Corporation
Revenue is down for the last 2 quarters, 69.51M → 55.59M (in $), with an average decrease of 20.0% per quarter
Netprofit is down for the last 2 quarters, 14.29M → 219.0K (in $), with an average decrease of 98.5% per quarter
In the last 1 year, Neurocrine Biosciences Inc. has given 27.7% return, outperforming this stock by 25.6%
0.74%
Downside
Day's Volatility :1.43%
Upside
0.7%
11.99%
Downside
52 Weeks Volatility :33.6%
Upside
24.55%
Period | Dynavax Technologies Corporation | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -17.87% | -0.5% | 0.0% |
6 Months | -20.32% | 5.9% | 0.0% |
1 Year | 2.13% | 3.1% | -1.9% |
3 Years | 41.68% | 14.2% | -21.8% |
Market Capitalization | 1.5B |
Book Value | $4.8 |
Earnings Per Share (EPS) | -0.05 |
PEG Ratio | 0.0 |
Wall Street Target Price | 25.75 |
Profit Margin | -2.75% |
Operating Margin TTM | -11.69% |
Return On Assets TTM | -1.92% |
Return On Equity TTM | -1.06% |
Revenue TTM | 232.3M |
Revenue Per Share TTM | 1.8 |
Quarterly Revenue Growth YOY | -69.89999999999999% |
Gross Profit TTM | 448.2M |
EBITDA | -26.1M |
Diluted Eps TTM | -0.05 |
Quarterly Earnings Growth YOY | -0.76 |
EPS Estimate Current Year | 0.26 |
EPS Estimate Next Year | 0.51 |
EPS Estimate Current Quarter | -0.01 |
EPS Estimate Next Quarter | 0.02 |
What analysts predicted
Upside of 125.28%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 8.2M | ↑ 2407.03% |
Net Income | -158.9M | ↑ 66.99% |
Net Profit Margin | -1.9K% | ↑ 27160.81% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 35.2M | ↑ 329.6% |
Net Income | -151.4M | ↓ 4.72% |
Net Profit Margin | -429.87% | ↑ 1508.4% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 46.6M | ↑ 32.18% |
Net Income | -91.8M | ↓ 39.38% |
Net Profit Margin | -197.15% | ↑ 232.72% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 439.4M | ↑ 844.0% |
Net Income | 76.7M | ↓ 183.59% |
Net Profit Margin | 17.46% | ↑ 214.61% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 722.7M | ↑ 64.45% |
Net Income | 293.2M | ↑ 282.15% |
Net Profit Margin | 40.56% | ↑ 23.1% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 232.3M | ↓ 67.86% |
Net Income | -6.4M | ↓ 102.18% |
Net Profit Margin | -2.75% | ↓ 43.31% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 167.7M | ↓ 34.6% |
Net Income | 63.8M | ↓ 50.44% |
Net Profit Margin | 38.04% | ↓ 12.16% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 184.5M | ↑ 9.99% |
Net Income | 67.7M | ↑ 6.15% |
Net Profit Margin | 36.71% | ↓ 1.33% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 46.9M | ↓ 74.57% |
Net Income | -24.3M | ↓ 135.92% |
Net Profit Margin | -51.85% | ↓ 88.56% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 60.2M | ↑ 28.39% |
Net Income | 3.4M | ↓ 114.1% |
Net Profit Margin | 5.69% | ↑ 57.54% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 69.5M | ↑ 15.38% |
Net Income | 14.3M | ↑ 316.58% |
Net Profit Margin | 20.56% | ↑ 14.87% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 55.6M | ↓ 20.02% |
Net Income | 219.0K | ↓ 98.47% |
Net Profit Margin | 0.39% | ↓ 20.17% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 210.9M | ↓ 3.61% |
Total Liabilities | 147.8M | ↑ 668.45% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 279.1M | ↑ 32.33% |
Total Liabilities | 270.8M | ↑ 83.18% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 353.3M | ↑ 26.59% |
Total Liabilities | 294.6M | ↑ 8.79% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.0B | ↑ 194.18% |
Total Liabilities | 816.9M | ↑ 177.3% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 985.9M | ↓ 5.14% |
Total Liabilities | 404.8M | ↓ 50.44% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 997.1M | ↑ 1.14% |
Total Liabilities | 375.0M | ↓ 7.36% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 999.3M | ↓ 2.31% |
Total Liabilities | 498.8M | ↓ 16.9% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 985.9M | ↓ 1.35% |
Total Liabilities | 404.8M | ↓ 18.83% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 969.9M | ↓ 1.62% |
Total Liabilities | 406.2M | ↑ 0.33% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 936.4M | ↓ 3.45% |
Total Liabilities | 359.2M | ↓ 11.56% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 972.9M | ↑ 3.9% |
Total Liabilities | 368.0M | ↑ 2.45% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 997.1M | ↑ 2.48% |
Total Liabilities | 375.0M | ↑ 1.9% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -131.3M | ↑ 69.38% |
Investing Cash Flow | 55.5M | ↓ 151.03% |
Financing Cash Flow | 99.1M | ↓ 47.26% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -121.3M | ↓ 7.65% |
Investing Cash Flow | -42.8M | ↓ 177.13% |
Financing Cash Flow | 154.4M | ↑ 55.8% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -92.3M | ↓ 23.92% |
Investing Cash Flow | -26.5M | ↓ 37.98% |
Financing Cash Flow | 109.5M | ↓ 29.06% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 335.5M | ↓ 463.71% |
Investing Cash Flow | 14.2M | ↓ 153.61% |
Financing Cash Flow | 55.8M | ↓ 49.06% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 62.7M | ↓ 81.31% |
Investing Cash Flow | -316.0M | ↓ 2321.41% |
Financing Cash Flow | 19.5M | ↓ 64.99% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 61.6M | ↑ 269.71% |
Investing Cash Flow | -119.0M | ↓ 326.75% |
Financing Cash Flow | 8.1M | ↑ 683.75% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 34.9M | ↓ 43.23% |
Investing Cash Flow | -33.0M | ↓ 72.31% |
Financing Cash Flow | 153.0K | ↓ 98.1% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 27.6M | ↓ 20.96% |
Investing Cash Flow | -52.3M | ↑ 58.75% |
Financing Cash Flow | -3.1M | ↓ 2119.61% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 28.0M | ↑ 1.54% |
Investing Cash Flow | 24.7M | ↓ 147.24% |
Financing Cash Flow | -294.0K | ↓ 90.49% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 31.1M | ↑ 10.99% |
Investing Cash Flow | -106.1M | ↓ 529.07% |
Financing Cash Flow | 3.0M | ↓ 1118.37% |
Sell
Neutral
Buy
Dynavax Technologies Corporation is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Dynavax Technologies Corporation | -1.79% | -20.32% | 2.13% | 41.68% | 41.68% |
Neurocrine Biosciences Inc. | -4.63% | 16.46% | 27.73% | 40.21% | 63.9% |
Haleon Plc Spon Ads | -0.25% | -2.88% | -6.68% | 9.31% | 9.31% |
Zoetis Inc. | -10.35% | -12.19% | -12.37% | -8.97% | 56.17% |
Viatris Inc. | -5.44% | 17.92% | 12.21% | -16.08% | -31.95% |
Catalent, Inc. | -0.32% | 22.03% | 22.78% | -48.65% | 30.48% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Dynavax Technologies Corporation | 31.59 | NA | 0.0 | 0.26 | -0.01 | -0.02 | NA | 4.8 |
Neurocrine Biosciences Inc. | 54.74 | 54.74 | 0.44 | 4.69 | 0.13 | 0.09 | NA | 22.61 |
Haleon Plc Spon Ads | 28.79 | 28.79 | 1.69 | 0.45 | 0.07 | 0.04 | 0.03 | 1.8 |
Zoetis Inc. | 29.48 | 29.48 | 2.58 | 5.8 | 0.5 | 0.13 | 0.01 | 10.9 |
Viatris Inc. | 226.4 | 226.4 | NA | 2.78 | 0.0 | 0.03 | 0.04 | 17.05 |
Catalent, Inc. | 211.02 | NA | 2.06 | 0.48 | -0.3 | -0.01 | NA | 20.41 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Dynavax Technologies Corporation | Buy | $1.5B | 41.68% | 31.59 | -2.75% |
Neurocrine Biosciences Inc. | Buy | $13.5B | 63.9% | 54.74 | 13.23% |
Haleon Plc Spon Ads | Buy | $37.0B | 9.31% | 28.79 | 9.28% |
Zoetis Inc. | Buy | $68.5B | 56.17% | 29.48 | 27.43% |
Viatris Inc. | Hold | $13.4B | -31.95% | 226.4 | 0.35% |
Catalent, Inc. | Hold | $10.1B | 30.48% | 211.02 | -31.77% |
BlackRock Inc
Federated Hermes Inc
State Street Corporation
Vanguard Group Inc
Goldman Sachs Group Inc
Deep Track Capital, LP
dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.
Organization | Dynavax Technologies Corporation |
Employees | 408 |
CEO | Mr. Ryan Spencer |
Industry | Health Technology |